Literature DB >> 24440526

Morphine modulates cell proliferation through mir133b &mir128 in the neuroblastoma SH-SY5Y cell line.

Veronica Gonzalez-Nunez1, Jose Antonio Noriega-Prieto2, Raquel E Rodríguez3.   

Abstract

Neuroblastoma is a childhood cancer with high incidence and high mortality rate. Great efforts are made to find new treatments and molecular markers for diagnosis and prognosis. miRNAs stand for novel strategies to modulate tumor growth, as they can act either as tumor suppressors or as oncogenes. Morphine is an opioid agonist widely used to treat severe and chronic pain, as for example cancer pain. Previous studies have revealed that morphine is able to modify cancer progression, by acting on proliferation or on apoptosis; however, up to date, the available results are contradictory, maybe due to the different doses used, routes of administration and model systems. While some studies show that morphine promotes cell proliferation and metastasis, other authors sustain that morphine effect is mainly antiproliferative and pro-apoptotic. In this study we aim to establish the effect of chronic opiate administration on cell proliferation in the neuroblastoma SH-SY5Y cell line. Low doses of morphine (10nM) promoted cell proliferation in undifferentiated cells and reduced the expression levels of miR133b, while higher doses (1μM) inhibited cell proliferation and correlated with decreased levels of miR133b and miR128 without triggering apoptosis. Naloxone, the classical opioid antagonist, could not fully block the effect of morphine on miR128 expression, so that the observed effect may be mediated by non-opioid mechanisms. Our results represent a further contribution to the hypothesis that a joint regulation of miRNA networks and the specific characteristics of the target tissue may determine the effect of morphine on tumor cell growth.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Morphine; OPRM1; Proliferation; SH-SY5Y; miR128; miR133b

Mesh:

Substances:

Year:  2014        PMID: 24440526     DOI: 10.1016/j.bbadis.2014.01.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Modulation of miR-139-5p on chronic morphine-induced, naloxone-precipitated cAMP overshoot in vitro.

Authors:  Dan-Ni Cao; Jing-Jing Shi; Ning Wu; Jin Li
Journal:  Metab Brain Dis       Date:  2018-06-18       Impact factor: 3.584

Review 2.  Chronic Cancer Pain: Opioids within Tumor Microenvironment Affect Neuroinflammation, Tumor and Pain Evolution.

Authors:  Angela Santoni; Matteo Santoni; Edoardo Arcuri
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

Review 3.  Opioids and Cancer Mortality.

Authors:  Jaya Amaram-Davila; Mellar Davis; Akhila Reddy
Journal:  Curr Treat Options Oncol       Date:  2020-02-20

Review 4.  Chronic opioid therapy in long-term cancer survivors.

Authors:  A Carmona-Bayonas; P Jiménez-Fonseca; E Castañón; A Ramchandani-Vaswani; R Sánchez-Bayona; A Custodio; D Calvo-Temprano; J A Virizuela
Journal:  Clin Transl Oncol       Date:  2016-07-21       Impact factor: 3.405

5.  Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells.

Authors:  Faizan H Khan; Vijayabaskar Pandian; Satishkumar Ramraj; Sheeja Aravindan; Terence S Herman; Natarajan Aravindan
Journal:  BMC Genomics       Date:  2015-07-07       Impact factor: 3.969

6.  MicroRNAs Are Involved in the Development of Morphine-Induced Analgesic Tolerance and Regulate Functionally Relevant Changes in Serpini1.

Authors:  Jenica D Tapocik; Kristin Ceniccola; Cheryl L Mayo; Melanie L Schwandt; Matthew Solomon; Bi-Dar Wang; Truong V Luu; Jacqueline Olender; Thomas Harrigan; Thomas M Maynard; Greg I Elmer; Norman H Lee
Journal:  Front Mol Neurosci       Date:  2016-03-24       Impact factor: 5.639

7.  MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolution.

Authors:  Natarajan Aravindan; Karthikeyan Subramanian; Dinesh Babu Somasundaram; Terence S Herman; Sheeja Aravindan
Journal:  Cancer Drug Resist       Date:  2019-12-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.